Biologic targeting in the treatment of inflammatory bowel diseases
The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which nonspecifically reduce inflammation and immunity have been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes a...
Main Authors: | Bosani, Matteo, Ardizzone, Sandro, Porro, Gabriele Bianchi |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2009
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726060/ |
Similar Items
-
Adalimumab for the treatment of Crohn’s disease
by: Cassinotti, Andrea, et al.
Published: (2008) -
Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]
Published: (2014) -
Targeting lymphatics in inflammatory bowel disease
by: D'Aiessio, Silvia, et al.
Published: (2015) -
Biologic Concentration Testing in Inflammatory Bowel Disease
by: Vaughn, Byron P., et al.
Published: (2015) -
Advances in the development of new biologics in inflammatory bowel disease
by: Ungar, Bella, et al.
Published: (2016)